Patients treated with hormone-modulating therapy for breast cancer had a reduced risk of developing Alzheimer disease or dementia compared with patients treated with other agents.
Breast Cancer - Female Anatomy: © peterschreiber.media - stock.adobe.com
A recent study identified that hormone-modulating therapy (HMT) has varying protective effects on the risk of Alzheimer disease and dementia in patients with breast cancer depending on their age and race.
The study, published in JAMA, assessed data from 18,808 women aged 65 and older who were diagnosed with breast cancer between 2007 and 2009. Medicare claims data were used to verify Alzheimer disease and dementia diagnoses, and patients who were diagnosed with Alzheimer disease or dementia or who had received HMT prior to the study window were excluded.
With an average of 12 years of follow-up, 23.7% of patients who received HMT (n = 2926) and 27.9% who did not receive HMT (n = 5622) developed Alzheimer disease or dementia. This demonstrated a 7% lower relative risk of Alzheimer disease or dementia with HMT (HR, 0.93; 95% CI, 0.88-0.98; P =.005).
This reduction in risk with HMT was most strongly seen in Black patients aged 65 to 75, where there was a 24% reduced risk (HR, 0.76; 95% CI, 0.88-0.95; P =.005). Conversely, White patients aged 65 to 74 only had an 11% risk reduction with HMT (HR, 0.89; 95% CI, 0.81-0.97). Generally, the associated risk reduction was lower for patients 75 years and older (HR, 0.81; 95% CI, 0.67-0.98).
For patients of other races, there was no significant association between HMT and Alzheimer disease or dementia risk (HR, 0.96; 95% CI, 0.90-1.02).
Investigators also looked at the relative risks of aromatase inhibitors vs selective estrogen receptor modulators (SERMs). Aromatase inhibitors like anastrozole, letrozole, and exemestane (Aromasin) showed a larger effect compared with SERMs, with HRs of 0.73 and 0.80, respectively. However, investigators noted that the results for SERMs like tamoxifen (Soltamox) and raloxifene (Evista) were not significant. SERMs did appear to be slightly more protective in White patients (HR, 0.81; 95% CI, 0.70-0.94). Selective estrogen receptor degraders like fulvestrant did not return significant results (HR, 0.37; 95% CI, 0.13-1.05; P =.06).
While investigators included estrogen receptor (ER) and progesterone receptor (PR) status as covariates, they noted the need for further research to potentially connect ER/PR status to Alzheimer disease and dementia risk.
“…while our results contribute valuable insights into the association of HMT with [Alzheimer disease and dementia] in the breast cancer population, further research is warranted to validate the observed associations in diverse populations and to elucidate the mechanisms underlying our observations,” study authors wrote.
Therapy Changes for Metastases and Toxicity Discussed in Breast Cancer
September 5th 2024During a Case-Based Roundtable® event, Ian Krop, MD, PhD, and event participants discussed how different types of metastases and treatment toxicity would affect therapy given to patients with triple-positive breast cancer in the second article of a 2-part series.
Read More
Participants Consider the Necessity of Chemo in HER2+ Breast Cancer
August 22nd 2024During a Case-Based Roundtable® event, Ian Krop, MD, PhD, discussed the use of chemotherapy in patients with HER2- and hormone receptor–positive metastatic breast cancer in combination with trastuzumab.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
FDA Lifts Partial Clinical Hold on Phase 1 YL202 Trial in NSCLC and Breast Cancer
August 19th 2024The FDA has lifted the partial clinical hold on the phase 1 YL202-INT-101-01 trial, allowing enrollment to resume in the US for patients with advanced NSCLC harboring EGFR mutations and HR-positive/HER2-negative breast cancer.
Read More